- EZZ exhibited at the TFWA World Exhibition and Conference in Cannes, France
- Conference largest gathering of professionals from duty free and travel retail sector
- EZZ flags move into Europe’s estimated $38.2 billion dietary supplement market
EZZ has exhibited at one of the world’s largest gatherings of professionals from the duty free and travel retail sectors in France as it flags a potential expansion into lucrative European market.
Genomic life science company EZZ Life Science (ASX:EZZ) exhibited at the prestigious TFWA World Exhibition and Conference in Cannes, France as it continues to enhance its presence on the world stage and considered a move into the European market.
EZZ has been adding to its distribution channels and geographies as it continues to grow its global footprint.
Over the past year the company has successfully added new distribution channels to its e-commerce strategy, including prominent platforms such as Amazon, eBay, and Chinese short video platform Kuaishou.
This strategic move has allowed consumers around the world greater access to EZZ’s high quality ranges of healthcare, haircare, and skincare products.
Its products are distributed in more than 20 countries worldwide.
Key markets include Australia, China, New Zealand and Singapore, where the brand has become synonymous with quality and efficacy.
Tapping into $38.2 billion European market
While EZZ’s global footprint is already substantial, participation in the TFWA World Exhibition and Conference marks the company’s first efforts to enter Europe’s estimated $38.2 billion dietary supplement market.
“EZZ’s participation in the TFWA World Exhibition and Conference for the first time highlights our commitment to exploring and seizing new avenues for growth,” EZZ chair Glenn Cross says.
“This marks a significant milestone in our journey, and we are eager to introduce our brand, values, and ground-breaking products to the European market.”
He says as the duty free and travel retail sector’s largest annual gathering, the TFWA World Exhibition & Conference offers an unrivalled scope for mixing with key industry decision-makers.
Strong growth for company
EZZ was recently selected by the Australian Financial Review as one of Australia’s top 100 companies seeing international revenue growth.
Preliminary results released at the end of August included record revenue growth of 147.3% to $37.1m in FY23.
Furthermore, EZZ is a finalist in the Life Sciences Category for the Australian Growth Company Awards with the winners announced on October 18.
The company has also been nominated as a finalist for the NSW Premier’s Export Award in the ecommerce category with the winners to be announced on October 23.
EZZ’s core focus has been on genomic health and developing a product pipeline of healthcare solutions based on genomics research.
The company’s health supplements, health food, haircare, children’s health, and probiotics under the brand EZZ.
It also has exclusive distribution rights for the EAORON brand of skin care products to pharmacies, supermarkets and specialist retailers in Australia and New Zealand.
This article was developed in collaboration with EZZ life Science, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.